Authors: Busse, D Yakes, FM Lenferink, AEG Arteaga, CL

Citation: D. Busse et al., Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistance, SEMIN ONCOL, 28(5), 2001, pp. 47-55

Authors: Muraoka, RS Lenferink, AEG Simpson, J Brantley, DM Roebuck, LR Yakes, FM Arteaga, CL

Citation: Rs. Muraoka et al., Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function, J CELL BIOL, 153(5), 2001, pp. 917-931

Authors: Lenferink, AEG Busse, D Flanagan, WM Yakes, FM Arteaga, CL

Citation: Aeg. Lenferink et al., ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways, CANCER RES, 61(17), 2001, pp. 6583-6591

Authors: Ballinger, SW Patterson, C Yan, CN Doan, R Burow, DL Young, CG Yakes, FM Van Houten, B Ballinger, CA Freeman, BA Runge, MS

Citation: Sw. Ballinger et al., Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells, CIRCUL RES, 86(9), 2000, pp. 960-966

Authors: Yakes, FM Wamil, BD Sun, FL Yan, HP Carter, CE Hellerqvist, CG

Citation: Fm. Yakes et al., CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis, CANCER RES, 60(20), 2000, pp. 5740-5746